Actively Recruiting
Randomized Study of GSK5784283 Compared to Placebo for Adults 40-80 Years with Moderate to Very Severe COPD
Led by GlaxoSmithKline · Updated on 2026-09-25
624
Participants Needed
4
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of GSK5784283 Felcorekibart compared with a placebo in adults aged 40 to 80 years who have moderate to very severe chronic obstructive pulmonary disease COPD with frequent flare-ups. This phase 3 trial aims to determine if adding GSK5784283 to standard care can better reduce the annual rate of moderate and severe COPD exacerbations. Participants will be randomly assigned to receive either GSK5784283 plus their usual COPD treatment or a matching placebo along with standard care. The study will last up to 78 weeks, during which the rate of COPD flare-ups, lung function changes, and quality of life will be assessed. Both groups will continue their regular COPD medications, including inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta-agonists. During the study, participants will have regular visits for health assessments, lung function tests, and questionnaires about respiratory symptoms and quality of life. Researchers will monitor safety and track how often moderate or severe COPD exacerbations occur. The main outcome measured is the annualized rate of these exacerbations up to week 78. The total study duration may be up to nearly four years, including follow-up and monitoring.
CONDITIONS
Brief Title
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here